United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chevron

Kenvue

Plains All American Pipeline

Philip Morris

AT&T

Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%. Therefore, sustainable dividend income and capital appreciation potential are essential for total return expectations.

Stock Market Looking Dangerous – 6 Safe Large Cap Dividend Blue Chips

Amgen

Exelon

Warren Buffett stocks can teach you a thing or two about investing. Warren Buffett's annual shareholders letter to Berkshire Hathaway (NYSE: BRK-A )(NYSE: BRK-B ) investors outlines what he's done the past year and often why.

Buffett's Backdoor Buys: 3 Stocks His Secret Portfolio Is Quietly Accumulating

Ares Capital

Enterprise Products Partners

Ares Capital is a leading business development company with a dividend yield of nearly 9.6%. Enterprise Products Partners has a growing distribution and good growth prospects.

3 Ultra-High-Yield Dividend Stocks That Could Realistically Double Your Money by 2030

Cathie Wood's Ark Genomic Innovation ETF has exited its position in Pfizer. Wood is likely disappointed with Pfizer's stock performance and its obesity drug setbacks.

Cathie Wood Is Selling This High-Yield Dividend Stock. Should You?

Axsome Therapeutics

CRISPR Therapeutics

Many investors appear to be underestimating Axsome Therapeutics. CRISPR Therapeutics has tremendous long-term prospects.

Buying These Dirt-Cheap Stocks Could Be a Brilliant Move

Broadcom

Delta Air Lines

Match Group

Micron Technology

Netflix

Select Medical Holdings

There are some stocks to make friends envious for March this year. These companies have impressive growth prospects and strong fundamentals that position them for potential outperformance.

7 Stocks That Will Make Your Friends Green with Envy

Moderna

Pfizer may be heading for long-term growth thanks to new products and a key acquisition. Moderna could soon have a new RSV vaccine on the market.

A Bull Market Is Here: 2 Magnificent Stocks Down 30% or More to Buy Right Now

Walgreens

After falling significantly, a pair of healthcare stocks offer above-average yields. New cancer drugs could lead to years of growth for Pfizer, but the pharma stock has been beaten down.

2 High-Yield Dividend Stocks Near 52-Week Lows. Time to Buy the Dips?

Pfizer would need to generate exceptional growth to reach a market cap of $1 trillion by 2035. Several obstacles could make achieving this goal difficult.

Will Pfizer Be a Trillion-Dollar Stock by 2035?

Alibaba

Intel

PayPal

Taiwan Semiconductor Manufacturing

The financial landscape is a dynamic arena with opportunities for the astute investor keen on solving its complexities. Within this broad spectrum of investment choices, entities exist that shine as ideals of innovation, steadfastness, and potential for expansion.

7 High-Value Stocks With Massive Wealth-Building Potential

Ares Commercial Real Estate

AGNC Investment

Ellington Financial

FS KKR Capital Corp

Realty Income Corp

Orchid Island Capital

Oxford Lane Capital

Paramount Global

PIMCO Dynamic Income Fund

Ready Capital Corp

Triplepoint Venture Growth BDC

Trinity Capital

Verizon

XAI Octagon Floating Rate & Alternative Income Term Trust

Prior to February 29, 2024 my REaders mentioned 32 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, these are ReFa/Ro. Ten analyst-target-estimated TOP-NET-GAIN Re/Fa/Ro: KVUE, PARA, OXLC, VZ,TPVC, O, PFE, FSC, RC, and EFC averaged 22.56% net gains from reader data collected 3/20/23. Ten analyst-target-augured February TOP-PRICE-UPSIDE reader faves & rogues (ReFa/Ro) were: FSK, TTE, CVX, VZ, KVUE, PARA, PFE, RC, O, & EFC boasting a 15.5% average target price upside estimate.

February Readers Noted 22 Ideal-To-Buy Dividend Dogs

Boston Properties

Kinder Morgan

Altria

Healthpeak Properties

Don't kick yourself if you didn't load up on investments returning 5% on your cash last year. They still can be found.

Juicy 5% Yields Are Now Rare — But They're Still Out There

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Wednesday, May 1, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Informa.

Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts

British American Tobacco

Dividend stocks are looking more and more attractive these days. Especially when you consider a given share of some companies can be prohibitively expensive.

3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50

Pfizer (PFE) plans to sell some shares of consumer healthcare firm Haleon (HLN), which it owns, to bring down its stake from 32% to 24%.

Pfizer (PFE) to Decrease Stake in Haleon From 32% to 24%

Haleon PLC

Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.

Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale

Haleon PLC (LSE:HLN, NYSE:HLN) said Pfizer Inc (NYSE:PFE, ETR:PFE) had sold a larger than expected amount of its shares overnight, scooping roughly £2.4 billion compared to the £2 billion expected, after the public offering was upsized.  The FTSE 100-listed consumer goods company said the US and international offer had been priced at £3.08 per ordinary share and $7.85 per American Depositary Shares.

Pfizer upsizes Haleon stake sale

News for Pfizer Stock (PFE)